NuPathe (PATH)
NuPathe Revenues
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PATH Revenues Range, Past 5 Years
| Minimum | 0.65M | Dec 2010 |
| Maximum | 0.65M | Dec 2010 |
| Average | 0.65M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these PATH related companies
PATH News
$SFE RT @NuPathe $PATH Did you miss NuPathe’s Q1 earnings call? Recording at http://stks.co/3oWB #migraine #patch
about 17 days ago by Safeguard
about 17 days ago by Safeguard
$PATH Did you miss NuPathe’s Q1 earnings call? Recording at http://stks.co/3mh1 #migraine #patch
about 20 days ago by NuPatheIR
about 20 days ago by NuPatheIR
$PATH NuPathe Q1 results http://stks.co/3lEl. Conference call at 8.30 http://stks.co/3lEm. #migraine #patch
about 21 days ago by NuPatheIR
about 21 days ago by NuPatheIR
NuPathe Announces First Quarter 2012 Financial Results and Operational Highlights
May 10, 7:30AM Marketwire
May 10, 7:30AM Marketwire
$PATH Don’t miss NuPathe Q1 results conference call tomorrow at 8.30am http://stks.co/3kEC #migraine #patch
about 22 days ago by NuPatheIR
about 22 days ago by NuPatheIR
$PATH Happy Mother’s Day! New NuPathe Innovating Neuroscience blog: Mothering with migraine http://stks.co/3ixE #migraine #patch
about 23 days ago by NuPatheIR
about 23 days ago by NuPatheIR
$PATH NuPathe Q1 results conference call on Thursday, May 10, at 8.30am http://stks.co/3gNG #migraine #patch
about 27 days ago by NuPatheIR
about 27 days ago by NuPatheIR
NuPathe to Report First Quarter 2012 Results and Hold Conference Call on Thursday, May 10, 2012
May 03, 8:30AM Marketwire
May 03, 8:30AM Marketwire
$PATH New NuPathe Innovating Neuroscience blog: big cost of non-compliance for schizophrenia patients http://stks.co/37Gg #schizophrenia
about 64 days ago by NuPatheIR
about 64 days ago by NuPatheIR
$PATH 200 Day SMA Cross - Price crossed above 200 day SMA (3.6168). Confirmed by volume.
about 70 days ago by TradeIdeasQuant
about 70 days ago by TradeIdeasQuant
$PATH is -5.1% down since open on unusual high volume and -2.5% down since close.
about 71 days ago by TradeBot
about 71 days ago by TradeBot
Needham & Company Maintains a 'Hold' on NuPathe (PATH); Continues Marching Forward
Mar 21, 7:55AM Street Insider
Mar 21, 7:55AM Street Insider
Wedbush believes $PATH could double or more in 2012 and raised its price target for shares to $18 from $17- attractive buying opportunity
about 72 days ago by ChiBullsTrader
about 72 days ago by ChiBullsTrader
$PATH 18 PT at Wedbush but needs to refill NDA and raise cash before a decent run-up trade can occur, 2H 2012
about 72 days ago by silverjet2
about 72 days ago by silverjet2
RT @VexTrades $PATH on watch. Wedbush bullish on it with an $18 target.
about 72 days ago by WallStJesus
about 72 days ago by WallStJesus
WEDBUSH positive on $PATH with 18 target -- could rocket the stock-- such a small float
about 72 days ago by ChiBullsTrader
about 72 days ago by ChiBullsTrader
RT @VexTrades $PATH on watch. Wedbush bullish on it with an $18 target.
about 72 days ago by ChiBullsTrader
about 72 days ago by ChiBullsTrader
Quant modell indicates a 2 - 1 chance for $PATH not closing below 4.02 today. Now trading at 4.14 or -7.9%
about 72 days ago by TradeBot
about 72 days ago by TradeBot
$PATH Resubmission of #Migraine Patch NDA Remains on Track for First Half 2012. @NuPathe Q4 and FY'11 Results http://stks.co/2xUO $SFE
about 72 days ago by Safeguard
about 72 days ago by Safeguard
RT @NuPatheIR $PATH NuPathe Q4 conference call starting at 8.30 am ET, webcast: http://stks.co/2xS6 #migraine #patch $SFE
about 72 days ago by Safeguard
about 72 days ago by Safeguard
$PATH NuPathe Q4 conference call starting at 8.30 am ET, webcast: http://stks.co/2xRx #migraine #patch
about 72 days ago by NuPatheIR
about 72 days ago by NuPatheIR
$PATH NuPathe Q4 2011 results out today http://stks.co/2xMF #migraine #patch
about 72 days ago by NuPatheIR
about 72 days ago by NuPatheIR
NuPathe Announces Resubmission of Migraine Patch NDA Remains on Track for the First Half of 2012
Mar 20, 7:30AM Benzinga
Mar 20, 7:30AM Benzinga
NuPathe Announces Fourth Quarter 2011 Financial Results and Operational Highlights
Mar 20, 7:30AM Marketwire
Mar 20, 7:30AM Marketwire
NuPathe to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 29, 8:00AM Marketwire
Feb 29, 8:00AM Marketwire
NuPathe Announces Allowance of Additional U.S. Patent Application for Its Migraine Patch
Jan 19, 4:09PM Benzinga
Jan 19, 4:09PM Benzinga
NuPathe Announces Third Quarter 2011 Financial Results and Operational Highlights
Nov 14, 4:05PM Marketwire
Nov 14, 4:05PM Marketwire
NuPathe to Report Third Quarter 2011 Results and Hold Conference Call on Monday, November 14, 2011
Nov 08, 5:37PM Marketwire
Nov 08, 5:37PM Marketwire
NuPathe to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 08, 9:02AM Marketwire
Nov 08, 9:02AM Marketwire
NuPathe Appoints Bart J. Dunn as Vice President, Corporate Development & Licensing
Nov 02, 9:00AM Marketwire
Nov 02, 9:00AM Marketwire
NuPathe Reports Positive Top-Line Results From 12-Month, Repeat Use Safety Trial for Its Migraine Patch
Oct 03, 8:30AM Marketwire
Oct 03, 8:30AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PATH | 3.12 | -0.06 | -1.89% | 46.02M |
| PARL | 5.78 | +0.00 | +0.00% | 120.05M |
| PAR | 5.12 | -0.02 | -0.39% | 77.92M |
| PANL | 28.15 | -1.09 | -3.73% | 1.349B |
| PAM | 4.67 | +0.00 | +0.00% | 245.50M |
| PAL | 2.28 | -0.05 | -2.15% | 379.70M |
| PAGG | 26.92 | -0.24 | -0.89% | |
| PAG | 24.58 | +0.16 | +0.66% | 2.206B |
| PACW | 22.81 | +0.00 | +0.00% | 813.86M |
| PACR | 5.65 | -0.14 | -2.42% | 202.53M |